{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T11:29:44Z","timestamp":1770982184530,"version":"3.50.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2009,12,18]],"date-time":"2009-12-18T00:00:00Z","timestamp":1261094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To estimate the cost-effectiveness of 10 mg rosuvastatin daily for older patients with systolic heart failure in the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This within trial analysis of CORONA used major cardiovascular (CV) events as the outcome measure. Resource use was valued and the costs of hospitalizations, procedures, and statin use compared. Cost-effectiveness was estimated as cost per major CV event avoided. There were significantly fewer major CV events in the rosuvastatin group compared with the placebo group (1.04 vs. 1.20 per patient; difference 0.164; 95% CI: 0.075\u20130.254, P &amp;lt; 0.001). The average cost of CV hospitalizations and procedures was significantly lower for those receiving rosuvastatin (\u00a31531 vs. \u00a31769; difference \u00a3238; 95% CI: \u00a373\u2013403, P = 0.005); the additional cost of the statin resulted in significantly higher total costs for the rosuvastatin group (\u00a31769 vs. \u00a32072; difference \u00a3303; 95% CI: \u00a3138\u2013468, P &amp;lt; 0.001). Overall, rosuvastatin was found to cost \u00a31840 (95% CI: \u00a3562\u20136028) per major CV event avoided.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This economic analysis showed that a significant reduction in major CV events with rosuvastatin led to significantly reduced costs of CV hospitalizations and procedures. The reduction in associated costs for major CV events was found to offset partially (by 44%) the cost of rosuvastatin treatment in patients with systolic heart failure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjhf\/hfp172","type":"journal-article","created":{"date-parts":[[2009,12,18]],"date-time":"2009-12-18T13:19:49Z","timestamp":1261142389000},"page":"66-74","source":"Crossref","is-referenced-by-count":15,"title":["An Economic Evaluation of Rosuvastatin Treatment in Systolic Heart Failure: Evidence from the CORONA Trial"],"prefix":"10.1093","volume":"12","author":[{"given":"Paula K.","family":"Lorgelly","sequence":"first","affiliation":[{"name":"Section of Public Health and Health Policy, Faculty of Medicine, University of Glasgow , Glasgow, G12 8RZ ,","place":["UK"]}]},{"given":"Andrew H.","family":"Briggs","sequence":"additional","affiliation":[{"name":"Section of Public Health and Health Policy, Faculty of Medicine, University of Glasgow , Glasgow, G12 8RZ ,","place":["UK"]}]},{"given":"Hans","family":"Wedel","sequence":"additional","affiliation":[{"name":"Nordic School of Public Health , G\u00f6teborg ,","place":["Sweden"]}]},{"given":"Peter","family":"Dunselman","sequence":"additional","affiliation":[{"name":"Amphia Hospital , Breda ,","place":["the Netherlands"]}]},{"given":"\u00c5ke","family":"Hjalmarson","sequence":"additional","affiliation":[{"name":"Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska Academy, Gothenburg University , Gothenburg ,","place":["Sweden"]}]},{"given":"John","family":"Kjekshus","sequence":"additional","affiliation":[{"name":"Rikshospitalet University Hospital, University of Oslo , Oslo ,","place":["Norway"]}]},{"given":"Finn","family":"Waagstein","sequence":"additional","affiliation":[{"name":"Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska Academy, Gothenburg University , Gothenburg ,","place":["Sweden"]}]},{"given":"John","family":"Wikstrand","sequence":"additional","affiliation":[{"name":"Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska Academy, Gothenburg University , Gothenburg ,","place":["Sweden"]}]},{"given":"Andr\u00e1s","family":"J\u00e1nosi","sequence":"additional","affiliation":[{"name":"Szent J\u00e1nos Hospital , Budapest ,","place":["Hungary"]}]},{"given":"Dirk J.","family":"van Veldhuisen","sequence":"additional","affiliation":[{"name":"University Medical Center , Groningen ,","place":["the Netherlands"]}]},{"given":"Vivencio","family":"Barrios","sequence":"additional","affiliation":[{"name":"Hospital Ram\u00f3n y Cajal , Madrid ,","place":["Spain"]}]},{"given":"C\u00e2ndida","family":"Fonseca","sequence":"additional","affiliation":[{"name":"S. Francisco Xavier Hospital, New University of Lisbon , Lisbon ,","place":["Portugal"]}]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Glasgow Cardiovascular Research Centre, Faculty of Medicine, University of Glasgow , Glasgow ,","place":["UK"]}]}],"member":"286","published-online":{"date-parts":[[2009,12,18]]},"reference":[{"key":"2026020203315892200_ejhfhfp172-bib-0001","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/j.ehj.2004.06.038","article-title":"Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study","volume":"25","author":"Bleumink","year":"2004","journal-title":"Eur Heart J"},{"key":"2026020203315892200_ejhfhfp172-bib-0002","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1161\/01.CIR.0000039105.49749.6F","article-title":"Lifetime risk for developing congestive heart failure: the Framingham Heart Study","volume":"106","author":"Lloyd-Jones","year":"2002","journal-title":"Circulation"},{"key":"2026020203315892200_ejhfhfp172-bib-0003","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/heart.89.1.49","article-title":"Heart failure and the aging population: an increasing burden in the 21st century?","volume":"89","author":"Stewart","year":"2003","journal-title":"Heart"},{"key":"2026020203315892200_ejhfhfp172-bib-0004","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1388-9842(01)00198-2","article-title":"The current cost of heart failure to the National Health Service in the UK","volume":"4","author":"Stewart","year":"2002","journal-title":"Eur J Heart Fail"},{"key":"2026020203315892200_ejhfhfp172-bib-0005","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/bmj.38993.731725.BE","article-title":"Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people","volume":"333","author":"Mihaylova","year":"2006","journal-title":"BMJ"},{"key":"2026020203315892200_ejhfhfp172-bib-0006","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/S0735-1097(02)01827-2","article-title":"Statins and chronic heart failure: do we need a large-scale outcome trial?","volume":"39","author":"Krum","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2026020203315892200_ejhfhfp172-bib-0007","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.ejheart.2005.09.005","article-title":"A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics","volume":"7","author":"Kjekshus","year":"2005","journal-title":"Eur J Heart Fail"},{"key":"2026020203315892200_ejhfhfp172-bib-0008","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N Engl J Med"},{"key":"2026020203315892200_ejhfhfp172-bib-0009","volume-title":"NHS reference costs 2005\u201306","author":"Department of Health"},{"key":"2026020203315892200_ejhfhfp172-bib-0010","volume-title":"Casemix Service","author":"The NHS Information Centre"},{"key":"2026020203315892200_ejhfhfp172-bib-0011","volume-title":"British National Formulary","author":"British Medical Association & Royal Pharmaceutical Society of Great Britain","year":"2006"},{"key":"2026020203315892200_ejhfhfp172-bib-0012","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.2517-6161.1954.tb00159.x","article-title":"Some problems in interval estimation","volume":"16","author":"Fieller","year":"1954","journal-title":"J R Stat Soc Series B-Statist Methodol"},{"key":"2026020203315892200_ejhfhfp172-bib-0013","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/hec.4730030505","article-title":"Costs, effects and C\/E-ratios alongside a clinical trial","volume":"3","author":"van Hout","year":"1994","journal-title":"Health Econ"},{"key":"2026020203315892200_ejhfhfp172-bib-0014","volume-title":"The Green Book: Appraisal and Evaluation in Central Government","author":"HM Treasury","year":"2007"},{"key":"2026020203315892200_ejhfhfp172-bib-0015","author":"Healthcare Commission"},{"key":"2026020203315892200_ejhfhfp172-bib-0016","volume-title":"Unit Costs of Health and Social Care 2006","author":"Netten","year":"2006"},{"key":"2026020203315892200_ejhfhfp172-bib-0017","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1093\/eurheartj\/ehl016","article-title":"Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme","volume":"27","author":"McMurray","year":"2006","journal-title":"Eur Heart J"},{"key":"2026020203315892200_ejhfhfp172-bib-0018","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ahj.2004.11.001","article-title":"Conducting economic evaluations alongside multinational clinical trials: toward a research consensus","volume":"149","author":"Reed","year":"2005","journal-title":"Am Heart J"},{"key":"2026020203315892200_ejhfhfp172-bib-0019","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(05)63014-0","article-title":"Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals","volume":"365","author":"Mihaylova","year":"2005","journal-title":"Lancet"},{"key":"2026020203315892200_ejhfhfp172-bib-0020","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","article-title":"EuroQol: the current state of play","volume":"37","author":"Brooks","year":"1996","journal-title":"Health Policy"},{"key":"2026020203315892200_ejhfhfp172-bib-0021","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/eurjhf\/hfn046","article-title":"Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide","volume":"11","author":"Wedel","year":"2009","journal-title":"Eur J Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1093%2Feurjhf%2Fhfp172","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/12\/1\/66\/66496622\/eurjhf_12_1_66.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/12\/1\/66\/66496622\/eurjhf_12_1_66.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T08:32:08Z","timestamp":1770021128000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/12\/1\/66\/8433716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,18]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2009,12,18]]},"published-print":{"date-parts":[[2010,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjhf\/hfp172","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,1]]},"published":{"date-parts":[[2009,12,18]]}}}